Yoshiya Tanaka, Satoshi Soen, Shintaro Hirata, Yosuke Okada, Saeko Fujiwara, Ikuko Tanaka, Yuriko Kitajima, Takuo Kubota, Kosuke Ebina, Yuichi Takashi, Reiko Inoue, Mika Yamauchi, Naoaki Okubo, Masanobu Ueno, Yasuhisa Ohata, Nobuaki Ito, Keiichi Ozono, Hisanori Nakayama, Masakazu Terauchi, Sakae Tanaka, Seiji Fukumoto
INTRODUCTION: Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months...
March 28, 2024: Journal of Bone and Mineral Metabolism